Merck & Co., Inc. Business Acquisition, Pro Forma Revenue
Merck & Co., Inc. (MRK) reported Business Acquisition, Pro Forma Revenue of $39.58 billion for the 12-month period ending 2015-12-31, per its 10-K filed 2018-02-27.
Discontinued › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2018-02-27
- Merck & Co., Inc. business acquisition, pro forma revenue for the quarter ending 2015-12-31 was $10.21B, a 5.57% decline year-over-year.
- Merck & Co., Inc. business acquisition, pro forma revenue for the quarter ending 2015-09-30 was $10.07B, a 7.30% decline year-over-year.
- Merck & Co., Inc. business acquisition, pro forma revenue for the quarter ending 2015-06-30 was $9.79B, a 12.85% decline year-over-year.
- Merck & Co., Inc. business acquisition, pro forma revenue for the quarter ending 2015-03-31 was $9.51B, a 9.63% decline year-over-year.
- Merck & Co., Inc. business acquisition, pro forma revenue for fiscal 2015 was $39.58B, a 8.87% decline from fiscal 2014.
- Merck & Co., Inc. business acquisition, pro forma revenue for fiscal 2014 was $43.44B.
- Merck & Co., Inc. business acquisition, pro forma revenue for fiscal 2009 was $45.96B.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 12 month |
|---|---|---|---|---|
| 2015-12-31 | $10.21B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $20.29B derived: sum of 2 quarters · filed 2018-02-27 | $30.07B derived: sum of 3 quarters · filed 2018-02-27 | $39.58B 10-K · filed 2018-02-27 |
| 2015-09-30 | $10.07B 10-Q · filed 2016-11-07 | $19.86B derived: sum of 2 quarters · filed 2016-11-07 | $29.37B 10-Q · filed 2016-11-07 | $40.19B derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-06-30 | $9.79B 10-Q · filed 2016-08-08 | $19.30B 10-Q · filed 2016-08-08 | $30.11B derived: sum of 3 quarters · filed 2017-02-28 | $40.98B derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-03-31 | $9.51B 10-Q · filed 2016-05-09 | $20.33B derived: sum of 2 quarters · filed 2017-02-28 | $31.19B derived: sum of 3 quarters · filed 2017-02-28 | $42.42B derived: sum of 4 quarters · filed 2017-02-28 |
| 2014-12-31 | $10.82B derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $21.68B derived: sum of 2 quarters · filed 2017-02-28 | $32.91B derived: sum of 3 quarters · filed 2017-02-28 | $43.44B 10-K · filed 2017-02-28 |
| 2014-09-30 | $10.87B 10-Q · filed 2015-11-05 | $22.09B derived: sum of 2 quarters · filed 2015-11-05 | $32.62B 10-Q · filed 2015-11-05 | |
| 2014-06-30 | $11.23B 10-Q · filed 2015-08-06 | $21.75B 10-Q · filed 2015-08-06 | ||
| 2014-03-31 | $10.53B 10-Q · filed 2015-05-07 | |||
| 2009-12-31 | $45.96B 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |